Navigation Links
Shire Reports Tolerability and Clinical Effects Results of Daytrana(R) (methylphenidate transdermal system) from Study in Adolescents with ADHD
Date:10/30/2009

ol and Prevention (CDC).

ADHD is a psychiatric behavioral disorder that manifests as a persistent pattern of inattention and/or hyperactivity-impulsivity that is more frequent and severe than is typically observed in individuals at a comparable level of development. The specific etiology of ADHD is unknown and there is no single diagnostic test for this disorder. Adequate diagnosis requires the use of medical and special psychological, educational, and social resources, utilizing diagnostic criteria such as Diagnostic and Statistical Manual of Mental Disorders-IV (DSM-IV®) or International Classification of Diseases 10 (ICD-10).

Although there is no cure for ADHD, there are accepted treatments that specifically target its symptoms. Standard treatments include educational approaches, psychological or behavioral modification, and medication.

SHIRE PLC

Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company's Web site: http://www.shire.com.

THE "SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

Statements included herein that are not his
'/>"/>

SOURCE Shire plc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Shire Continues to Deliver Excellent Growth From Core Products
2. Shire to Present Important Study Findings on its ADHD Treatments at a Major Psychiatric Meeting on October 29 and 30
3. Shire Presents Results of Five Lialda(R) (mesalamine) Analyses at ACG 2009 Annual Scientific Meeting
4. Shire Targets Fourth Quarter Filing of BLA for REPLAGAL(R) for Fabry Disease With U.S. FDA
5. Shire and Sandoz Settle all Pending Litigation Concerning ADDERALL XR(R)
6. Veriscrip and DAMMAD Team Up to Combat Prescription Drug Abuse in New Hampshire
7. New Hampshire Rx Card Launching Statewide
8. Shire Announces FDA Approval of Once-Daily INTUNIV(TM) (guanfacine) Extended Release Tablets for the Treatment of ADHD in Children and Adolescents Aged 6 to 17
9. Shire Completes Submission of NDA for Velaglucerase Alfa for Type 1 Gaucher Disease and Reports Positive Results for Remaining Two Phase III Trials
10. Shire Reports Positive Results From First of Three Phase III Trials of velaglucerase alfa for Type 1 Gaucher Disease and Provides Important Updates on Interactions With FDA
11. Shire Receives Fast Track Designation for velaglucerase alfa for Gaucher Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... -- , Revenues from continuing operations of $1.9 ... EPS from continuing operations of $1.08, up 1.9% versus  prior ... $0.92, 7% below prior year , Cash from operations ... Full year 2014 revenues now expected to be up 2.5% ... Full year 2014 adjusted diluted EPS range narrowed to  $4.00 ...
(Date:7/24/2014)... July 24, 2014 HIGHLIGHTS:Q2 2014 Results ... , Reported sales increased 3% to $701 million.  Sales ... rates added one percentage point to sales growth. , ... 6% in Applied and 1% in SAFC Commercial. , ... 2013, an increase of 13%.  Adjusted diluted EPS in Q2 ...
(Date:7/24/2014)... --  ndd Medical Technologies , a leader in innovative ... announced that its EasyOne Pro ® has been ... Capacity (DLCO) for phase 2 of the COPDGene ® ... Pulmonary Disease (COPD) ever undertaken.  COPD is now the ... affects millions of people worldwide.  In ...
Breaking Medicine Technology:Quest Diagnostics Reports Second Quarter 2014 Financial Results 2Quest Diagnostics Reports Second Quarter 2014 Financial Results 3Quest Diagnostics Reports Second Quarter 2014 Financial Results 4Quest Diagnostics Reports Second Quarter 2014 Financial Results 5Quest Diagnostics Reports Second Quarter 2014 Financial Results 6Quest Diagnostics Reports Second Quarter 2014 Financial Results 7Quest Diagnostics Reports Second Quarter 2014 Financial Results 8Quest Diagnostics Reports Second Quarter 2014 Financial Results 9Quest Diagnostics Reports Second Quarter 2014 Financial Results 10Quest Diagnostics Reports Second Quarter 2014 Financial Results 11Quest Diagnostics Reports Second Quarter 2014 Financial Results 12Quest Diagnostics Reports Second Quarter 2014 Financial Results 13Quest Diagnostics Reports Second Quarter 2014 Financial Results 14Quest Diagnostics Reports Second Quarter 2014 Financial Results 15Quest Diagnostics Reports Second Quarter 2014 Financial Results 16Quest Diagnostics Reports Second Quarter 2014 Financial Results 17Quest Diagnostics Reports Second Quarter 2014 Financial Results 18Quest Diagnostics Reports Second Quarter 2014 Financial Results 19Quest Diagnostics Reports Second Quarter 2014 Financial Results 20Quest Diagnostics Reports Second Quarter 2014 Financial Results 21Quest Diagnostics Reports Second Quarter 2014 Financial Results 22Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 2Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 3Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 4Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 5Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 6Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 7Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 8Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 9Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 10Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 11Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 12Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 13Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 14Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 15
... and Company (NYSE: LLY ) announced that ... Clinical Endocrinology website, showed that Axiron® (testosterone) topical solution ... study objective to restore testosterone levels to the normal ... testosterone. In addition, secondary outcomes showed that the treatment ...
... Wis., June 28, 2011 Novelos Therapeutics, Inc. ... for treatment and diagnosis of cancer, today announced that ... the defendants, motion to dismiss the putative federal securities ... Court for the District of Massachusetts in March 2010 ...
Cached Medicine Technology:Newly Published Study Showed Axiron® (testosterone) Topical Solution Restored Testosterone Levels to Normal Range in Hypogonadal Men 2Newly Published Study Showed Axiron® (testosterone) Topical Solution Restored Testosterone Levels to Normal Range in Hypogonadal Men 3Newly Published Study Showed Axiron® (testosterone) Topical Solution Restored Testosterone Levels to Normal Range in Hypogonadal Men 4Newly Published Study Showed Axiron® (testosterone) Topical Solution Restored Testosterone Levels to Normal Range in Hypogonadal Men 5Newly Published Study Showed Axiron® (testosterone) Topical Solution Restored Testosterone Levels to Normal Range in Hypogonadal Men 6Novelos Therapeutics Announces Dismissal of Putative Federal Securities Class Action Lawsuit 2Novelos Therapeutics Announces Dismissal of Putative Federal Securities Class Action Lawsuit 3
(Date:7/24/2014)... 24, 2014 The Biofeedback ... a new distribution agreement with game development company ... the two groups to offer Zukor's Grind ... biofeedback and neurofeedback in European and international markets. ... developed expressly to be used as a biofeedback/neurofeedback ...
(Date:7/24/2014)... July 24, 2014 The North American air ... billion in 2014, and is expected to register a CAGR ... has been the biggest market for the air and missile ... U.S. market has witnessed budget cuts as well. , Browse ... defense radar market report, to get an idea of the ...
(Date:7/24/2014)... Steven Reinberg HealthDay ... Children covered by Medicaid, the publicly funded insurance program for ... more often than uninsured or privately insured youngsters, a U.S. ... than those with private insurance to visit for a reason ... survey conducted by the U.S. Centers for Disease Control and ...
(Date:7/24/2014)... News) -- Even though its use is often advised by ... does not help treat lower back pain, according to a ... was no more effective than a dummy pill for more ... Besides showing no effect in easing discomfort, the study also ... tied to back pain, nor did it improve patients, overall ...
(Date:7/24/2014)... (PRWEB) July 24, 2014 While healthcare ... in providing quality interpretation services to non-English speakers within ... down. According to Common Sense Advisory, the language ... to $2.3 billion in 2016 (1); additionally, officials at ... to shift over to video remote interpreting ...
Breaking Medicine News(10 mins):Health News:Biofeedback Federation of Europe Enters Distribution Agreement with Zukor Interactive 2Health News:Biofeedback Federation of Europe Enters Distribution Agreement with Zukor Interactive 3Health News:North America Air and Missile Defense Radar Market is Expected to Reach $2.7 Billion in 2020 - New Report by MicroMarket Monitor 2Health News:North America Air and Missile Defense Radar Market is Expected to Reach $2.7 Billion in 2020 - New Report by MicroMarket Monitor 3Health News:North America Air and Missile Defense Radar Market is Expected to Reach $2.7 Billion in 2020 - New Report by MicroMarket Monitor 4Health News:Many Kids With Medicaid Use ER as Doctor's Office: CDC 2Health News:Many Kids With Medicaid Use ER as Doctor's Office: CDC 3Health News:Acetaminophen May Not Help Against Back Pain, Study Contends 2Health News:Acetaminophen May Not Help Against Back Pain, Study Contends 3Health News:Stratus Video Interpreting Predicts $1 Billion Market Shift to Video Remote Interpreting by 2016 as Court and Healthcare Systems Heed Cost-Effectiveness 2Health News:Stratus Video Interpreting Predicts $1 Billion Market Shift to Video Remote Interpreting by 2016 as Court and Healthcare Systems Heed Cost-Effectiveness 3Health News:Stratus Video Interpreting Predicts $1 Billion Market Shift to Video Remote Interpreting by 2016 as Court and Healthcare Systems Heed Cost-Effectiveness 4
... Supported Efficacy, Safety and Tolerability of ... with Schizophrenia -, TOKYO and PRINCETON, N.J., ... Squibb Company (NYSE: BMY ) announced today ... the supplemental New,Drug Application for the atypical antipsychotic ...
... be lifesavers, study suggsts , TUESDAY, Nov. 6 (HealthDay ... artery bypass graft (CABG) surgery reduces a patient,s risk ... the Cleveland Clinic, included more than 5,200 patients who ... overall incidence of post-operative stroke one year after surgery ...
... To help raise awareness about the,prevalence of ... serving our country, TriWest Healthcare Alliance has contributed,$50,000 ... TBI. "According to the Department of Defense, ... members sustaining injuries in the Global War,on Terror ...
... Focus on Growth Businesses, LEHIGH VALLEY, Pa., Nov. ... Chemie AG are in advanced discussions over Wacker,s,purchase of ... Systems (WPS) and Air Products Polymers (APP), including APP,s,vinyl ... and,Wacker 35 percent. As for WPS, Wacker owns 80 ...
... 7 The Disabled American,Veterans (DAV) is commending ... the largest increase in funding for the Department ... on Congress and the,Administration to support this important ... Military Construction and Veterans Affairs Appropriations bill,calls for ...
... QED International Associates Inc.,administrator for the HealthShares(TM) ... today announced that effective at the,opening of trading ... GIVN ) will replace Dade Behring Holdings, ... Index, and Inverness Medical Innovations,(Amex: IMA ) ...
Cached Medicine News:Health News:U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for Adolescent Patients With Schizophrenia 2Health News:U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for Adolescent Patients With Schizophrenia 3Health News:U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for Adolescent Patients With Schizophrenia 4Health News:U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for Adolescent Patients With Schizophrenia 5Health News:U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for Adolescent Patients With Schizophrenia 6Health News:U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for Adolescent Patients With Schizophrenia 7Health News:U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for Adolescent Patients With Schizophrenia 8Health News:TriWest Contributes $50,000 to Bob Woodruff Family Fund for Traumatic Brain Injury 2Health News:Air Products in Advanced Discussions With Wacker Over Polymers Business 2Health News:VA Budget Earns High Praise 2Health News:QED International Associates Announces Changes to the HealthShares(TM) Composite, and the HealthShares(TM) Diagnostics Indexes 2
This kit has been designed for the quantitative,determination of total immunoreactive intact PTH (Total,Intact PTH) in blood samples. The Total Intact PTH,level is the sum of PTH (1-84) and N-t...
Fully automated immunochemiluminometric assay for the rapid intraoperative,measurement of Intact PTH 1-84 using human serum or EDTA plasma....
... exclusively distributed by Medtronic, sets the ... intra-operative imaging with surgical navigation in ... is one of the most comprehensive ... Exceptional image quality from a low-field ...
... nm and 940 nm) laser system is ... solid-state laser quickly and effectively treats vascular ... offers the clinical versatility to precisely target ... vessels in a convenient, affordable package. , ...
Medicine Products: